COVID-19: CDC, FDA and CMS Guidance
This page includes AHA Today stories and other AHA content on coronavirus COVID-19 guidance from the CDC, FDA, and CMS.
AHA urged the Centers for Medicare & Medicaid Services to provide flexibility regarding the agency’s new COVID-19 test documentation requirement for the diagnostic-related group add-on payment.
AHA urges the Centers for Medicare & Medicaid Services to provide additional flexibility regarding the agency’s new COVID-19 test documentation requirement for the diagnostic-related group (DRG) add-on payment.
The Centers for Medicare & Medicaid Services issued an interim final rule that, among other provisions, makes collecting and reporting COVID-19-data a condition of participation for hospitals that participate in Medicare.
The Food and Drug Administration issued an emergency use authorization for investigational convalescent plasma to treat suspected or laboratory-confirmed COVID-19 in hospitalized patients.
The Food and Drug Administration authorized emergency use of a rapid point-of-care antigen test to detect SARS-CoV-2 directly from nasal swab specimens.
The Centers for Disease Control and Prevention released a study examining how COVID-19 is affecting American Indians and Alaska Natives — one of the populations at highest risk for the disease.
The Food and Drug Administration released a resource to help U.S. health care providers select respirators for their health care facility.
One in four U.S. counties, or 818, were COVID-19 hotspots for at least one day in the period between March 8 and July 15, representing 80% of the U.S. population, according to a report released by the Centers for Disease Control and Prevention.
The Centers for Disease Control and Prevention updated its guidance for determining when health care personnel with confirmed or suspected COVID-19 may return to work.
A test kit made by Thermo Fisher Scientific to detect COVID-19 from respiratory specimens may produce false positive results, the Food and Drug Administration warned.